Abstract
Growth hormone-releasing peptides (GHRPs) and growth hormone-releasing hormone (GHRH) analogs represent two classes of secretagogues that stimulate pulsatile GH release via distinct receptors. This review compares Ipamorelin, CJC-1295, Sermorelin, and Tesamorelin in preclinical research contexts.
Peptide Comparison
Ipamorelin
- Structure: 5-amino acid ghrelin mimetic
- Receptor: GHS-R1a (growth hormone secretagogue receptor)
- Half-life: Approximately 2 hours
- Selectivity: Minimal effects on cortisol and prolactin reported
CJC-1295 (with DAC)
- Structure: GHRH(1-29) with drug affinity complex
- Receptor: GHRH receptor
- Half-life: Extended (6-8 days) due to albumin binding
- Feature: Longest acting in class
Sermorelin
- Structure: GHRH(1-29)-NH2
- Receptor: GHRH receptor
- Half-life: Short (10-20 minutes)
- History: Previously FDA-approved for pediatric use
Tesamorelin
- Structure: trans-3-hexenoyl-GHRH(1-44)-NH2
- Receptor: GHRH receptor
- Half-life: 30-60 minutes
- Status: FDA-approved for specific indication
Research Applications
- GH Axis Studies: Pulsatile release pattern research
- Metabolic Research: Body composition studies
- Musculoskeletal: Bone and muscle research
- Wound Healing: Repair mechanism studies
- Combination Studies: GHRP + GHRH synergy research
Synergistic Effects
Research has examined the combination of GHS-R1a and GHRH-R pathway activation, with studies reporting enhanced GH release compared to either class alone.
Current Research Status
These peptides are well-characterized in preclinical research. Sermorelin and Tesamorelin have regulatory history, while Ipamorelin and CJC-1295 remain primarily research compounds.